Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases
- PMID: 9580921
- DOI: 10.1159/000029240
Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases
Abstract
Chemical pleurodesis is an effective treatment of malignant pleural effusions, but indications must be individualised to optimise its results. The aim of the present study was to investigate the relationship of various prognostic features with both the response rate to pleurodesis and the probability of patient survival. A non-concurrent cohort study was carried out in which 120 evaluable patients with malignant pleural effusion underwent pleurodesis. Lung (40%), breast (26.6%), and unknown primary site (12.5%) carcinomas were the most frequent neoplasms. Clinical data and pleural fluid parameters were analysed. Median overall survival was 9 months. Pleural fluid glucose (< 60 mg/dl), Karnofsky performance status (< 70), size of the effusion in chest radiographs (massive effusion), pleural fluid pH (< 7.20), presence of concomitant alterations in chest radiographs, and pleural lactic acid dehydrogenase levels (> 600 U/l) showed a significant association with the probability of failure. Patients with these features, along with those having non-chemosensitive tumours (in particular, non-small cell lung cancer), had a significantly worse actuarial survival. This study confirms that some pretreatment clinical data and pleural fluid parameters can predict both the outcome of pleurodesis and the survival of patients with malignant pleural effusion.
Similar articles
-
Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion.Ann Intern Med. 1997 May 15;126(10):768-74. doi: 10.7326/0003-4819-126-10-199705150-00003. Ann Intern Med. 1997. PMID: 9148649
-
Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data.Chest. 2000 Jan;117(1):87-95. doi: 10.1378/chest.117.1.87. Chest. 2000. PMID: 10631204 Clinical Trial.
-
Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease.Chest. 2000 Jan;117(1):73-8. doi: 10.1378/chest.117.1.73. Chest. 2000. PMID: 10631202
-
Management of malignant pleural effusions.Monaldi Arch Chest Dis. 2001 Oct;56(5):394-9. Monaldi Arch Chest Dis. 2001. PMID: 11887496 Review.
-
Current trends in pleurodesis.Curr Opin Pulm Med. 1997 Jul;3(4):319-25. Curr Opin Pulm Med. 1997. PMID: 9262121 Review.
Cited by
-
Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases.Int J Clin Oncol. 2012 Oct;17(5):470-6. doi: 10.1007/s10147-011-0312-5. Epub 2011 Oct 7. Int J Clin Oncol. 2012. PMID: 21979749
-
Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion.Medicine (Baltimore). 2016 Jun;95(26):e3996. doi: 10.1097/MD.0000000000003996. Medicine (Baltimore). 2016. PMID: 27368006 Free PMC article.
-
A new sterilization technique with balloon-tube thoracostomy for thoracic empyema.Jpn J Thorac Cardiovasc Surg. 2003 Sep;51(9):413-9. doi: 10.1007/BF02719593. Jpn J Thorac Cardiovasc Surg. 2003. PMID: 14529156
-
Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.Thorax. 2014 Dec;69(12):1098-104. doi: 10.1136/thoraxjnl-2014-205285. Epub 2014 Aug 6. Thorax. 2014. PMID: 25100651 Free PMC article.
-
Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.Oncol Lett. 2017 Sep;14(3):3657-3662. doi: 10.3892/ol.2017.6631. Epub 2017 Jul 20. Oncol Lett. 2017. PMID: 28927127 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources